AEOLUS PHARMACEUTICALS, INC.
AOLS evidence brief
What we can confirm
- BioSniper Score:
- 3.3 / 10
- Market Cap:
- $15K
- Lead Asset:
- aeol 10150 (Preclinical)
What it means
What to watch
Prepared research question
What matters most for AOLS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$15K
Cash Runway
—
Lead Asset
aeol 10150 (Preclinical)
Next Catalyst
—
Tracking 2 pipeline candidates for AEOLUS PHARMACEUTICALS, INC..
Run AEOLUS PHARMACEUTICALS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available AEOLUS PHARMACEUTICALS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Preclinical
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Frequently asked questions
What is AEOLUS PHARMACEUTICALS, INC.'s lead drug candidate?
AEOLUS PHARMACEUTICALS, INC.'s most advanced tracked candidate is aeol 10150 (Preclinical) for Oncology (in combination with radiation therapy) and medical countermeasure against pulmonary effects of radiation exposure (ARS/Delayed Effects of Acute Radiation Exposure).
Where is AEOLUS PHARMACEUTICALS, INC. headquartered?
AEOLUS PHARMACEUTICALS, INC. (AOLS) is headquartered in Mission Viejo, CA, United States.
What therapeutic areas does AEOLUS PHARMACEUTICALS, INC. focus on?
AEOLUS PHARMACEUTICALS, INC. develops therapies across Oncology, Rare Disease, Neurology, Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.